Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme
19.2.2026 14:00:00 EET | Business Wire | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme
“With the T-Rex Ultra 2, we focused on building a watch for people who rely on navigation, endurance, and on-watch decision-making in demanding environments,” said Scott Shepley, Head of Global Marketing at Amazfit. “It’s designed for long, complex routes where preparation and reliability matter, and it complements the T-Rex 3 Pro within the T-Rex family by serving a more expedition-focused use case.”
Designed to Go the Distance
Featuring a 1.5-inch AMOLED display, scratch-resistant sapphire glass, and a Grade 5 titanium bezel and case back, the T-Rex Ultra 2 is engineered to withstand harsh conditions above and below the surface, with 10 ATM water resistance and dual diving certification supporting demanding outdoor and underwater use. With up to 30 days of battery life in smartwatch mode and more than 50 hours of GPS tracking, the Ultra 2 is built to support extended, multi-day adventures without compromise. Featuring 64 GB of built-in storage, users can save maps, music, and activities directly on the watch for extended adventures without needing their phone.
Built for Night and Low-Visibility Conditions
The Ultra 2 features a built-in dual-mode flashlight with adjustable brightness, a low-interference green light that allows users to clearly view the watch screen while wearing night vision goggles, and an SOS signal for emergencies. Activate Boost Mode for an industry-leading burst of light when navigating night treks or urgent situations.
Navigation Without Limits
For the first time in the T-Rex lineup, full-color global maps come preloaded in the Zepp app, allowing users to quickly and easily install the area they need to the watch to create point-to-point routes, search nearby points of interest, and automatically reroute without needing a phone or network. With advanced GPS tracking supported by six satellite systems, the Ultra 2 delivers fast, accurate positioning and reliable turn-by-turn navigation. Map data has been refined to better distinguish terrain types, while smoother interactions and optimized alerts improve on-watch navigation. Additional navigation enhancements include expanded offline route planning up to 100 km, faster route rerouting, improved elevation profiles, and smarter climb segmentation to provide clearer insight into upcoming ascents.
Smarter Route Management
For long and technical routes, the T-Rex Ultra 2 introduces intelligent Checkpoint Display and Reminder alerts, enabling users to set key milestones such as water sources, shelters, altitude targets, or turnaround points. Enhanced climb segmentation and optimized elevation profiles provide clearer insight into upcoming ascents, helping users better manage pacing and energy throughout an effort.
Performance Tools for Serious Exploration
Additional features include grade-adjusted pace for more accurate performance metrics on hilly terrain, voice memo recording during workouts, and a built-in speaker and microphone for Bluetooth calls and audible alerts. The watch integrates seamlessly with the Zepp app, providing insights into training, recovery, sleep, nutrition and overall health.
Pricing and Availability
The T-Rex Ultra 2 will be available for purchase starting February 19, 2026, for $549.99 on Amazfit.com and Amazon.
About Amazfit
Amazfit, a global smart wearable and fitness leader, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.
Amazfit builds smart wearables designed around movement — training with intention, recovery with balance, and evolution over time. Built for the way people train today, Amazfit blends endurance, strength, and recovery into a single, coherent rhythm to support sustainable progress over time.
Behind Amazfit is Zepp, which builds the intelligence that supports its training experience. For more information, visit www.amazfit.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219679075/en/
Contacts
Media Contacts
Max Borges Agency for Amazfit
amazfit@maxborgesagency.com
Mary Thompson Woodbury
Head of PR, Amazfit North America
Mary.woodbury@zepp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom